Clinical trial

Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial

Name
OPMICS-1
Description
The purpose of the trial is to identify the "most simple non-inferior of three different methods", placebo, laparoscopic assisted transverse abdominal plane block (L-TAP) and ultrasound guided TAP block (US-TAP), using postoperative opioid consumption as a measure of efficacy in patients undergoing elective minimally invasive colon surgery in an ERAS setting. Postoperative pain scores and length of stay (LOS) will also be measured. The simplicity of the three methods is ranked as: 1) placebo, 2) L-TAP and 3) US-TAP.
Trial arms
Trial start
2021-01-14
Estimated PCD
2024-08-31
Trial end
2024-12-31
Status
Recruiting
Phase
Early phase I
Treatment
Active drug
Injection of Ropivacaine
Arms:
Laparoscopic assisted TAP, Ultrasound-guided TAP
Other names:
Ropivacaine
Placebo
Injection of Saline solution
Arms:
Laparoscopic assisted TAP, Placebo, Ultrasound-guided TAP
Other names:
Saline solution
Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block
Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
Arms:
Ultrasound-guided TAP
Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block
Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
Arms:
Laparoscopic assisted TAP
Injection of placebo - Ultrasound-guided transverse abdominal plane block
Lateral ultrasound-guided transverse abdominal plane block with saline solution
Arms:
Laparoscopic assisted TAP, Placebo
Injection of placebo - Laparoscopic assisted transverse abdominal plane block
Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
Arms:
Placebo, Ultrasound-guided TAP
Size
360
Primary endpoint
Total morphine dose equivalents administered.
The first 24 hours from the end of anesthesia.
Eligibility criteria
Inclusion Criteria: * Patients planned to receive curative elective minimally invasive colon surgery for colon cancer or adenoma without a planned ostomy. Colon cancer or adenoma is defined by a distance of more than 15 cm from the anal verge to the distal limitation of the tumour or adenoma as measured by rigid sigmoidoscope. The following procedural codes are included: * Laparoscopic ileocecal resection * Laparoscopic right hemicolectomy * Other laparoscopic resection of both small and large bowel * Laparoscopic resection of transverse colon * Laparoscopic left hemicolectomy * Laparoscopic resection of sigmoid colon * Other laparoscopic colon resection * Having given informed written consent. Exclusion Criteria: * Known allergy to local analgesics * Known liver failure Class C according to the Child-Pugh Score * Body weight of less than 40 kg * History of being a chronic pain patient (weekly intake WHO step II or step III or adjuvant step I analgesic) * Presence of concomitant painful conditions other than low back pain that could confound the subject's trial assessments or self-evaluation of the index pain, e.g., syndromes with widespread pain such as fibromyalgia * Predictably non-compliant due to language barrier or psychiatric disease * Patients rescheduled for open surgery, before the intervention has been administered * Patients where the indication for surgery changes before the intervention has been administered * Patients with known inflammatory bowel disease * Patients who have previously undergone open major abdominal surgery defined by prior intraabdominal surgery with a midline or upper abdominal incision of more than 8 cm * Incisional hernia * Patients with a history of abdominal wall surgery including resection of the external oblique muscles, the internal oblique muscles, the transversus abdominis muscles, the rectus abdominis muscles or their fascial components * Pregnancy (patients are screened using urine human chorionic gonadotropin upon admission if female and not postmenopausal).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 360, 'type': 'ESTIMATED'}}
Updated at
2023-10-03

1 organization

1 product

1 drug

7 indications

Indication
Pain
Indication
Postoperative
Indication
Abdominal
Indication
Analgesic
Indication
Surgery
Indication
Colon Cancer
Indication
Injection Site